Companies / Slovenia
Krka Opens API Plant
June 2007 | Company News AlertLeading Slovenian drugmaker Krka has officially opened its Sinteza 4 active pharmaceutical ingredient (API) production facility. The EUR80mn (US$107mn) plant will allow the firm to manufacture most of its APIs by itself, thereby saving considerable funds, which be diverted to R&D. BMI expects the output of the factory to sell well, given the vast patient populations that the pharmaceuticals produced there address. Accordingly, we believe that Krka will reinforce its position as Slovenia's premier company and enhance its reputation a major player in the Central & Eastern European generics sphere.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
